4/A: Milestone Pharma CEO Amends Stock Option Price
Executive Compensation Disclosure Amendment
Milestone Pharmaceuticals' President and CEO, Joseph Oliveto, filed an amended Form 4 to correct the exercise price of his employee stock options to $1.96.
Summary
- An amendment to a previously filed Form 4 was submitted by Joseph Oliveto, President and CEO of Milestone Pharmaceuticals Inc.
- The amendment corrects the exercise price of employee stock options previously reported.
- The correct exercise price for the options is $1.96 per share.
- The options cover a total of 679,000 common shares.
- The vesting schedule for these options is one-fourth (1/4th) of the shares on February 2, 2027, followed by one thirty-sixth (1/36th) of the remaining shares vesting each month thereafter.
- The options have an expiration date of February 2, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative correction, clarifying executive compensation details without impacting operational or financial performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The exercise price on the initial filings was incorrectly stated.
Industry Context
StockSavvy.ai notes that this filing is a routine administrative correction of an executive compensation disclosure. Such amendments are common in regulatory reporting to ensure accuracy in insider transaction details and do not typically reflect broader industry trends or operational shifts.
Comparison to Industry Standards
- This filing represents a standard regulatory correction for an executive compensation disclosure, aligning with common compliance practices across publicly traded companies. It does not provide data for direct comparison to specific company performance benchmarks or project results.
Stakeholder Impact
- Shareholders: Provides clarity and accuracy regarding executive compensation details, ensuring transparency in insider holdings.
Key Dates
| Date | Description |
|---|---|
| 02/02/2026 | Earliest transaction date for the employee stock option grant. |
| 02/04/2026 | Date of the original Form 4 filing that is being amended. |
| 02/05/2026 | Date the amended Form 4/A was signed and filed. |
| 02/02/2027 | First vesting date for one-fourth of the shares subject to the option. |
| 02/02/2036 | Expiration date of the employee stock options. |
Recommendation
holdThe filing is an administrative correction of an executive stock option exercise price and does not contain any new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation.
Keywords
Milestone Pharmaceuticals, MIST, Joseph Oliveto, SEC Form 4/A, Stock Options, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.